Table 1 (abstract P298). Dynamics of SLE features pre-rituximab and during rituximab treatment
From: Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)
Parameter | SLE onset | RTX (baseline) | p1 | Last visit (LV) | p2 | p3 |
|---|---|---|---|---|---|---|
SLEDAI | 23 (16.0; 26) | 18,0 (8,0; 26,0) | 0.003 | 4 (2,0; 8.0) | 0.0015 | 0.000001 |
ANA, titer | 5120 (1280;10240) | 820 (240; 3200) | 0.345 | 640 (160; 1280) | 0.515 | 0.0014 |
Anti-dsDNA, U/ml (n.v.<25) | 150 (48; 237) | 36 (7,7;148) | 0.263 | 12 (0; 65) | 0.05 | 0.001 |
Proteinuria, g/l | 1.0 (0.5; 3,5) | 0.6 (0.3; 3.7) | 1.0 | 0,17 (0; 0.9) | 0.05 | 0.0008 |
Hematuria, # cells | 15 (0; 42) | 15 (5; 50) | 0.170 | 0 (0; 2,5) | 0.088 | 0.003 |
C4, g/l | 0.11 (0.06; 0.4) | 0.13 (0.06; 0.24) | 0.715 | 0.16 (0.1; 0.2) | 0.042 | 0.0066 |
Active LN n, (%) | 25 (100) | 15 (60.0) | 0.001 | 8 (32.0) | 0.048 | 0.001 |
Patients with GCS therapy n, (%) | 23 (92) | 24 (96) | 0.522 | 16 (64) | 0.005 | 0.004 |
Corticosteroids, mg/kg | 1.0 (0.7; 1.0) | 0.8 (0.23; 1.0) | 0.148 | 0.2 (0.1; 0.9) | 0.001 | 0.0002 |